Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT02847091

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02847091
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02847091. Allocation not applicable; no masking; primary purpose treatment. Start 2016-07-29 (actual); primary completion 2017-11-09 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ipragliflozin
Intervention (Drug)
Insulin
Lead sponsor
Astellas Pharma Inc (class: industry)

Record details

Record id
cardio:ct-nct02847091
Content hash
d8b4d28432e318090bec8516431a9268619439c8d5286db0c7a3cdfe16c64f1d